Abstract
Pulmonary Hypertension (PH) related to Left Heart Disease (LHD) is the most common form of PH, accounting for more than two third of all PH cases. The hemodynamic abnormalities seen in PHLHD are complex, and there are currently minimal evidence-based recommendations for the management of PH-LHD. While it is accepted that PH in the context of left heart disease is a marker of worse prognosis, it remains unclear whether its primary treatment is beneficial or harmful. In this article, we discuss the prevalence and significance of PH in patients with Heart Failure (HF) with Reduced Ejection Fraction (HFrEF) as well as HF with Preserved Ejection Fraction (HFpEF), and those with valvular heart disease and provide insights into the complex pathophysiology of cardiopulmonary interrelationship in individuals with PH due to left heart disease. Furthermore, we provide a framework for diagnostic testing and an approach to optimal management of these complex patients based on current European Society of Cardiology (ESC) guidelines.
Keywords: Pulmonary hypertension, left heart disease, heart failure, pulmonary vascular resistance, pulmonary vasodilator, valvular heart disease.
Current Vascular Pharmacology
Title:Pulmonary Hypertension secondary to Left Heart Disease
Volume: 16 Issue: 6
Author(s): Ghazal Kabbach and Debabrata Mukherjee*
Affiliation:
- Department of Internal Medicine, Texas Tech University Health Science Center, El Paso, TX 79905,United States
Keywords: Pulmonary hypertension, left heart disease, heart failure, pulmonary vascular resistance, pulmonary vasodilator, valvular heart disease.
Abstract: Pulmonary Hypertension (PH) related to Left Heart Disease (LHD) is the most common form of PH, accounting for more than two third of all PH cases. The hemodynamic abnormalities seen in PHLHD are complex, and there are currently minimal evidence-based recommendations for the management of PH-LHD. While it is accepted that PH in the context of left heart disease is a marker of worse prognosis, it remains unclear whether its primary treatment is beneficial or harmful. In this article, we discuss the prevalence and significance of PH in patients with Heart Failure (HF) with Reduced Ejection Fraction (HFrEF) as well as HF with Preserved Ejection Fraction (HFpEF), and those with valvular heart disease and provide insights into the complex pathophysiology of cardiopulmonary interrelationship in individuals with PH due to left heart disease. Furthermore, we provide a framework for diagnostic testing and an approach to optimal management of these complex patients based on current European Society of Cardiology (ESC) guidelines.
Export Options
About this article
Cite this article as:
Kabbach Ghazal and Mukherjee Debabrata *, Pulmonary Hypertension secondary to Left Heart Disease, Current Vascular Pharmacology 2018; 16 (6) . https://dx.doi.org/10.2174/1570161115666170913105424
DOI https://dx.doi.org/10.2174/1570161115666170913105424 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
PUFA for Human Health: Diet or Supplementation?
Current Pharmaceutical Design Let Them Eat Cake
Current Nutrition & Food Science Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Recent Advances on Neural Tube Defects with Special Reference to Valproic Acid
Endocrine, Metabolic & Immune Disorders - Drug Targets Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Nonsteroidal Anti-Inflammatory Drugs: Exploiting Bivalent COXIB/ TP Antagonists for the Control of Cardiovascular Risk
Current Medicinal Chemistry Short Term, Low Dose Simvastatin Pretreatment Alters Memory Immune Function Following Secondary Staphylococcus aureus Infection
Current Pharmaceutical Biotechnology Anesthetic Considerations for Electroconvulsive Therapy-Especially Hemodynamic and Respiratory Management
Current Psychiatry Reviews Preface (Hot Topic: Medicinal Strategies in the Treatment of Obesity Guest Editor: Akio Inui)
Current Medicinal Chemistry - Central Nervous System Agents Psychosocial Risk Factors and Ischemic Heart Disease: A New Perspective
Reviews on Recent Clinical Trials Role of the Autonomic Nervous System in the Endothelial Dysfunction of the Metabolic Syndrome
Current Hypertension Reviews HDL Elevators and Mimetics - Emerging Therapies for Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Editorial (Thematic Issue: Advances in The Therapy of Atrial Fibrillation: Incrementally Progressive But Not Without Missteps)
Current Cardiology Reviews Editorial (Novel Therapies and Botanical and Mechanical Approaches for Management of Cardiovascular Disease)
Recent Patents on Cardiovascular Drug Discovery Bioconversion of Isoflavones into Bioactive Equol: State of the Art
Recent Patents on Food, Nutrition & Agriculture Fenofibrate, Homocysteine and Renal Function
Current Vascular Pharmacology New Anti-Anginal Drugs: Ranolazine
Cardiovascular & Hematological Agents in Medicinal Chemistry Fibrin Clot Properties and Cardiovascular Disease
Vascular Disease Prevention (Discontinued) The Role of Psychiatrist in Organ Transplantation: From Gate-keeper to Patient's Advocate
Current Psychiatry Reviews Insulin Secretion and Interleukin-1β Dependent Mechanisms in Human Diabetes Remission After Metabolic Surgery
Current Medicinal Chemistry